{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-007973","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2025-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.203870+00:00","generated_at":"2026-05-17T04:14:36.629494+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeOnc subsidiary NuroMENA signs MSA with M42's IROS for UAE Phase 2b/3 trial of NEO100; board expanded","bullets":["MSA with IROS (affiliate of M42 and Mubadala) covers clinical research services in UAE for CNS cancer therapies.","First work order: Phase 2b/3 study of intranasal NEO100 in progressive/recurrent GBM and Grade III astrocytomas.","Estimated budget of $2.4M in service fees plus $0.1M pass-through costs, milestone-based payments.","NuroMENA board expands with Waleed K. Al Ali (CEO of Quazar Investment) and its Chairman, alongside Amir Heshmatpour and others.","Company retains all IP and data from studies under MSA; agreement governed by Abu Dhabi Global Market law."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-007973","json":"https://secwatch.observer/filing/0001829126-25-007973.json","markdown":"https://secwatch.observer/filing/0001829126-25-007973.md","text":"https://secwatch.observer/filing/0001829126-25-007973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625007973/0001829126-25-007973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625007973/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:14:36.629494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}